{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:40:35Z","timestamp":1790138435769,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T00:00:00Z","timestamp":1414627200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s12879-014-0565-5","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T11:21:46Z","timestamp":1414581706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study"],"prefix":"10.1186","volume":"14","author":[{"given":"Naho","family":"Tsuchiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panita","family":"Pathipvanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuanjun","family":"Wichukchinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archawin","family":"Rojanawiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wattana","family":"Auwanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koya","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pathom","family":"Sawanpanyalert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,30]]},"reference":[{"issue":"1","key":"565_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","volume":"43","author":"FJ Palella Jr","year":"2006","unstructured":"Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006, 43 (1): 27-34. 10.1097\/01.qai.0000233310.90484.16.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"565_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/QAI.0b013e3181967602","volume":"50","author":"S Chasombat","year":"2009","unstructured":"Chasombat S, McConnell MS, Siangphoe U, Yuktanont P, Jirawattanapisal T, Fox K, Thanprasertsuk S, Mock PA, Ningsanond P, Lertpiriyasuwat C, Pinyopornpanich S: National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr. 2009, 50 (5): 506-512. 10.1097\/QAI.0b013e3181967602.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"565_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.7883\/yoken.66.375","volume":"66","author":"P Pathipvanich","year":"2013","unstructured":"Pathipvanich P, Tsuchiya N, Rojanawiwat A, Schmidt WP, Auwanit W, Sawanpanyalert P, Ariyoshi K: Changing burden of HIV\/AIDS to clinical settings in Northern Thailand over 15 years. Jpn J Infect Dis. 2013, 66 (5): 375-378.","journal-title":"Jpn J Infect Dis"},{"issue":"6","key":"565_CR4","doi-asserted-by":"publisher","first-page":"e10490","DOI":"10.1371\/journal.pone.0010490","volume":"5","author":"C Cesar","year":"2010","unstructured":"Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, Wolff M, Pape JW, Leger P, Padgett D, Madero JS, Gotuzzo E, Sued O, McGowan CC, Masys DR, Cahn PE: Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One. 2010, 5 (6): e10490-10.1371\/journal.pone.0010490.","journal-title":"PLoS One"},{"issue":"1","key":"565_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1468-1293.2007.00417.x","volume":"8","author":"J Zhou","year":"2007","unstructured":"Zhou J, Paton NI, Ditangco R, Chen YM, Kamarulzaman A, Kumarasamy N, Lee CK, Li PC, Merati TP, Phanuphak P, Pujari S, Vibhagool A, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG: Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med. 2007, 8 (1): 8-16. 10.1111\/j.1468-1293.2007.00417.x.","journal-title":"HIV Med"},{"issue":"8","key":"565_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1089\/aid.2009.0274","volume":"26","author":"SW Cardoso","year":"2010","unstructured":"Cardoso SW, Grinsztejn B, Velasque L, Veloso VG, Luz PM, Friedman RK, Morgado M, Ribeiro SR, Moreira RI, Keruly J, Moore RD: Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses. 2010, 26 (8): 865-874. 10.1089\/aid.2009.0274.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"565_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/01.qai.0000188123.15493.43","volume":"41","author":"N Kumarasamy","year":"2006","unstructured":"Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, Saghayam S, Flanigan TP, Carpenter CC, Solomon S, Mayer KH: Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr. 2006, 41 (1): 53-58. 10.1097\/01.qai.0000188123.15493.43.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"565_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/1471-2334-12-296","volume":"12","author":"MC Prosperi","year":"2012","unstructured":"Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondi A, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S: Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis. 2012, 12: 296-10.1186\/1471-2334-12-296.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"565_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1468-1293.2009.00750.x","volume":"11","author":"P Cicconi","year":"2010","unstructured":"Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A: Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010, 11 (2): 104-113. 10.1111\/j.1468-1293.2009.00750.x.","journal-title":"HIV Med"},{"issue":"2","key":"565_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00002030-200501280-00011","volume":"19","author":"J Ananworanich","year":"2005","unstructured":"Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, Phanuphak P, Ruxrungtham K, Lange J, Cooper DA: Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS. 2005, 19 (2): 185-192. 10.1097\/00002030-200501280-00011.","journal-title":"AIDS"},{"issue":"10","key":"565_CR11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","volume":"15","author":"E Martinez","year":"2001","unstructured":"Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A, Gatell JM: Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001, 15 (10): 1261-1268. 10.1097\/00002030-200107060-00007.","journal-title":"AIDS"},{"issue":"6","key":"565_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008, 358 (6): 568-579. 10.1056\/NEJMoa0706135.","journal-title":"N Engl J Med"},{"issue":"4","key":"565_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1086\/650003","volume":"50","author":"W Wangsomboonsiri","year":"2010","unstructured":"Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, Kiertiburanakul S, Charoenyingwattana A, Komindr S, Thongnak C, Mushiroda T, Nakamura Y, Chantratita W, Sungkanuparph S: Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin Infect Dis. 2010, 50 (4): 597-604. 10.1086\/650003.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"565_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","volume":"19","author":"S Chantarangsu","year":"2009","unstructured":"Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y: HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics. 2009, 19 (2): 139-146. 10.1097\/FPC.0b013e32831d0faf.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"565_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/QAI.0b013e31805d8ae3","volume":"45","author":"R Kiguba","year":"2007","unstructured":"Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, Katabira E: Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr. 2007, 45 (2): 218-223. 10.1097\/QAI.0b013e31805d8ae3.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"565_CR16","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1017\/S0950268812002397","volume":"141","author":"N Tsuchiya","year":"2013","unstructured":"Tsuchiya N, Pathipvanich P, Rojanawiwat A, Wichukchinda N, Koga I, Koga M, Auwanit W, Kilgore PE, Ariyoshi K, Sawanpanyalert P: Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in northern Thailand. Epidemiol Infect. 2013, 141 (9): 1840-1848. 10.1017\/S0950268812002397.","journal-title":"Epidemiol Infect"},{"key":"565_CR17","unstructured":"Scaling up Antiretroviral Therapy in Resource-Limited Settings. 2002"},{"issue":"12","key":"565_CR18","first-page":"1925","volume":"91","author":"S Sungkanuparph","year":"2008","unstructured":"Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, Chetchotisakd P, Kiertiburanakul S, Tansuphaswadikul S, Buppanharun W, Manosuthi W, Techasathit W, Ratanasuwan W, Tantisiriwat W, Suwanagool S, Leechawengwongs M, Ruxrungtham K: Guidelines for Antiretroviral Therapy in HIV-1 Infected Adults and Adolescents: The Recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008, 91 (12): 1925-1936.","journal-title":"J Med Assoc Thai"},{"issue":"4","key":"565_CR19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2478\/abm-2010-0066","volume":"4","author":"S Sungkanuparph","year":"2010","unstructured":"Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, Leechawengwongs M, Ruxrungtham K, Phanuphak P: Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents. Asian Biomedicine. 2010, 4 (4): 515-528.","journal-title":"Asian Biomedicine"},{"issue":"1","key":"565_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archinternmed.2009.432","volume":"170","author":"L Elzi","year":"2010","unstructured":"Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M: Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010, 170 (1): 57-65. 10.1001\/archinternmed.2009.432.","journal-title":"Arch Intern Med"},{"issue":"3","key":"565_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1468-1293.2007.00451.x","volume":"8","author":"E Hart","year":"2007","unstructured":"Hart E, Curtis H, Wilkins E, Johnson M: National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients. HIV Med. 2007, 8 (3): 186-191. 10.1111\/j.1468-1293.2007.00451.x.","journal-title":"HIV Med"},{"key":"565_CR22","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1097\/00126334-200412150-00005","volume":"37","author":"SN Pujari","year":"2004","unstructured":"Pujari SN, Patel AK, Naik E, Patel KK, David A, Patel JK, Mane AA, Bhagat S: Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr. 2004, 37: 1566-1569. 10.1097\/00126334-200412150-00005.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9256","key":"565_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","volume":"357","author":"E Martinez","year":"2001","unstructured":"Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell JM: Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001, 357 (9256): 592-598. 10.1016\/S0140-6736(00)04056-3.","journal-title":"Lancet"},{"issue":"3","key":"565_CR24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/135965350901400307","volume":"14","author":"DM Zannou","year":"2009","unstructured":"Zannou DM, Denoeud L, Lacombe K, Amoussou-Guenou D, Bashi J, Akakpo J, Gougounon A, Akonde A, Ade G, Houngbe F, Girard PM: Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther. 2009, 14 (3): 371-380.","journal-title":"Antivir Ther"},{"key":"565_CR25","first-page":"1","volume":"5","author":"R Pavlos","year":"2012","unstructured":"Pavlos R, Phillips EJ: Individualization of antiretroviral therapy. Pharmacogenomics Pers Med. 2012, 5: 1-17.","journal-title":"Pharmacogenomics Pers Med"},{"issue":"1","key":"565_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","volume":"19","author":"AM Martin","year":"2005","unstructured":"Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen FT, Mallal S: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005, 19 (1): 97-99. 10.1097\/00002030-200501030-00014.","journal-title":"AIDS"},{"issue":"2","key":"565_CR27","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1097\/QAI.0b013e31827ca50f","volume":"62","author":"E Phillips","year":"2013","unstructured":"Phillips E, Bartlett JA, Sanne I, Lederman MM, Hinkle J, Rousseau F, Dunn D, Pavlos R, James I, Mallal SA, Haas DW: Associations between HLA-DRB1*0102, HLA-B*5801, and Hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013, 62 (2): e55-e57. 10.1097\/QAI.0b013e31827ca50f.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"565_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/QAD.0b013e3282f37812","volume":"22","author":"ZG Vitezica","year":"2008","unstructured":"Vitezica ZG, Milpied B, Lonjou C, Borot N, Ledger TN, Lefebvre A, Hovnanian A: HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008, 22: 539-544. 10.1097\/QAD.0b013e3282f37812.","journal-title":"AIDS"},{"issue":"12","key":"565_CR29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","volume":"20","author":"R Littera","year":"2006","unstructured":"Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, Corso N, Casula B, La Nasa G, Contu L, Manconi PE: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS. 2006, 20 (12): 1621-1626. 10.1097\/01.aids.0000238408.82947.09.","journal-title":"AIDS"},{"issue":"2","key":"565_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","volume":"21","author":"H Gatanaga","year":"2007","unstructured":"Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, Tachikawa N, Kikuchi Y, Oka S: HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS. 2007, 21 (2): 264-265. 10.1097\/QAD.0b013e32801199d9.","journal-title":"AIDS"},{"issue":"1","key":"565_CR31","first-page":"1","volume":"40","author":"N Tsuchiya","year":"2009","unstructured":"Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, Saeng-aroon S, Auwanit W, Matsuyama A, Sawanpanyalert P, Ariyoshi K: Demographic, socio-economic, behavioral and clinical factors predicting vilorogic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand. Southeast Asian J Trop Med Public Health. 2009, 40 (1): 1-12.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"565_CR32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/135965350501000409","volume":"10","author":"M John","year":"2005","unstructured":"John M, Moore CB, James IR, Mallal SA: Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1. Antivir Ther. 2005, 10: 551-555.","journal-title":"Antivir Ther"},{"key":"565_CR33","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1069660","volume":"296","author":"CB Moore","year":"2002","unstructured":"Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA: Evidence of HIV adoptation to HLA-restricted immune responses at a population level. Science. 2002, 296: 1439-1443. 10.1126\/science.1069660.","journal-title":"Science"},{"key":"565_CR34","first-page":"1","volume":"5","author":"R Palvis","year":"2012","unstructured":"Palvis R, Phillips EJ: Individualization of antiretroviral therapy. Pharmacogenomics and Personalized Medicine. 2012, 5: 1-17.","journal-title":"Pharmacogenomics and Personalized Medicine"},{"issue":"10","key":"565_CR35","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1128\/CVI.00169-07","volume":"14","author":"G Ahlenstiel","year":"2007","unstructured":"Ahlenstiel G, Roomp K, Da\u00a8umer M, Nattermann J, Vogel M, Rockstroh KJ, Niko B, Rolf K, Hans-Dieter N, Sauerbruch T, Lengauer T: Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level. Clin Vaccine Immunol. 2007, 14 (10): 1266-1273. 10.1128\/CVI.00169-07.","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"565_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/QAD.0b013e3283350eef","volume":"24","author":"W Manosuthi","year":"2010","unstructured":"Manosuthi W, Butler DM, P\u00e9rez-Santiago J, Poon FYA, Pillai KS, Mehta SR, Pacold ME, Richman DD, Pond SK, Smith DM: Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure. AIDS. 2010, 24 (3): 411-416. 10.1097\/QAD.0b013e3283350eef.","journal-title":"AIDS"},{"issue":"12","key":"565_CR37","doi-asserted-by":"publisher","first-page":"e28691","DOI":"10.1371\/journal.pone.0028691","volume":"6","author":"A Gupta","year":"2011","unstructured":"Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, Hosseinipour M, Gummadi N: Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011, 6 (12): e28691-10.1371\/journal.pone.0028691.","journal-title":"PLoS One"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-014-0565-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-014-0565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-014-0565-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-014-0565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T21:10:19Z","timestamp":1650489019000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-014-0565-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,30]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1186\/s12879-014-0565-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,30]]},"assertion":[{"value":"30 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"565"}}